

# CLINICAL TRIALS FORUM 2021

The most impactful trials of the year in cardiovascular medicine and diabetes.

**GUEST TRIALIST**



**DEEPAK BHATT**  
MD, MPH, FACC, FAHA, FSCAI, FESC

Executive Director of Interventional Cardiovascular Programs,

Brigham and Women's Hospital  
Heart & Vascular Center

Professor of Medicine,  
Harvard Medical School  
Boston, MA

**CO-CHAIR**



**NARENDRA SINGH**  
MD, FRCPC, FCCS, FACC, FAHA

Director, Clinical Research, NSC  
Cardiology,  
Medical College of Georgia,  
Augusta and Mercer Universities,

Clinician Scientist and Co-  
Director, CCRN  
Atlanta, GA

**CO-CHAIR**



**MILAN GUPTA**  
MD, FRCPC, FCCS, FACC

Associate Clinical Professor  
McMaster University  
Medical Director, CCRN  
Brampton, ON

Discuss the design, results, and clinical implications of major cardiovascular trials presented in 2021 that inform patient care.

## CLINICAL QUESTION

Is there a role for SGLT2 inhibitors in heart failure regardless of ejection fraction?

What is the current role for incretin therapies in CV risk reduction and obesity management?

What are the latest treatment options for patients with chronic kidney disease?

What are the latest advances in structural heart disease?

## KEY TRIALS

EMPEROR-Preserved, SOLOIST-WHF, CHIEF-HF, EMPULSE

AMPLITUDE, SURPASS, STEP Programs

CREDENCE, DAPA-CKD, FIDELIO and FIGARO-DKD

LAAOS III, AVATAR

This program was developed by CCRN and received an unrestricted educational grant from Gold- AstraZeneca and Boehringer Ingelheim; Silver - Bayer and BMS/Pfizer.

